Genetics & Molecular Biology

Nicole Dale

GLP-1 Drug Discovery Success Transformed Pharmaceutical R&D

Pharmatica photorealistic illustration of GLP-1 drug discovery showing peptide molecules, metabolic signalling pathways, and obesity treatment research in a modern pharmaceutical laboratory.

From gut hormones to global therapeutics, GLP-1 drug discovery transformed obesity treatment through peptide engineering and incretin biology translation.

Nicole Dale

FDA Generic Peptides Guidance Sets New Expectations

Pharmatica visual of the FDA generic peptides guidance showing peptide molecular structure and regulatory assessment of generic peptide medicines.

Revised FDA draft guidance for generic peptide products updates expectations for ANDAs, impurities, structure, immune response, and biological activity.

Shubhangi Dua

Could Biological Ageing Be the Next Big Shift in Drug Discovery?

“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."

Nicole Dale

AI in GMP Manufacturing: Are Regulators Ready for Digital Factories?

Pharmatica image representing AI in pharmaceutical GMP manufacturing using machine learning, predictive maintenance, digital quality management, continuous manufacturing, and smart pharmaceutical production.

Learn how AI in pharmaceutical GMP manufacturing is improving quality, data integrity, predictive maintenance, and regulatory compliance in modern drug production.

Nicole Dale

Nanocarriers Target the Eye for Better Ocular Drug Delivery

Pharmatica image representing ocular drug delivery using nanocarriers to improve therapeutic targeting of the eye and retinal tissues.

Ocular drug delivery faces major biological barriers. Nanocarriers could improve bioavailability, tissue targeting, controlled release, and treatment for difficult eye diseases.

Shubhangi Dua

How Should Pharma Companies Audit AI Vendors?

“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."